Insilico Medicine Receives FDA Fast Track Designation for ISM6331, the AI-driven Pan-TEAD Inhibitor, in Advanced Mesothelioma

RegulatoryISM6331Positive

AI Analysis

Summary

Insilico Medicine announced that ISM6331, an AI-driven pan-TEAD inhibitor, has received FDA Fast Track designation for the treatment of advanced mesothelioma. Fast Track designation expedites development and review of the drug candidate.

Outcome Details

Fast Track Designation granted

Importance:6/10

Sentiment:

0.80

FDA Fast TrackISM6331Pan-TEAD InhibitorAI-driven drug discoverymesothelioma

Related Companies

$INTI $SHWZ

Read the original article

Published by Drugs.com Clinical Trial Results on July 29, 2026 11:07 PM

Read Original